References of "Deroisy, Rita"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPain relief is not a confounder in joint space narrowing assessment of full extension knee radiographs
Pavelka, K.; Rovati, Lucio C; Gatterova, J. et al

in Annals of the Rheumatic Diseases (2002, June), 61(Suppl.1), 118

Detailed reference viewed: 19 (10 ULiège)
Full Text
Peer Reviewed
See detailAdministration of a supplement containing both calcium and vitamin D is more effective than calcium alone to reduce secondary hyperparathyroidism in postmenopausal women with low 25(OH)vitamin D circulating levels
Deroisy, Rita ULiege; Collette, Julien ULiege; Albert, Adelin ULiege et al

in Aging Clinical & Experimental Research (2002), 14(1), 13-17

Background and aims: Supplementation of postmenopausal women with calcium alone or calcium-vitamin D association was suggested to have positive effects on bone turnover and bone density, as well as to ... [more ▼]

Background and aims: Supplementation of postmenopausal women with calcium alone or calcium-vitamin D association was suggested to have positive effects on bone turnover and bone density, as well as to lower fracture incidence. The beneficial effect appears to be mediated by a reduction in parathyroid hormone secretion. Our aim was to compare the respective efficacy of calcium and calcium-vitamin D supplements in reducing serum parathyroid hormone levels in postmenopausal women with prevalent low 25(OH)vitamin D levels. Methods: One hundred consecutive ambulatory postmenopausal women with serum 25(OH)vitamin D levels below 18 ng/mL were included in a randomized, prospective, open label study. For a duration of 90 days, the women were randomly assigned to a daily supplementation of either one tablet of calcium gluconolactate and carbonate (500 mg calcium), or one powder-pack of an association of calcium carbonate (500 mg calcium), citric acid (2.175 gr) and cholecalciferol (200 IU). Changes observed during the 90 days of the study in circulating PTH levels were the primary endpoint, while changes in serum 25(OH)D levels were assessed as secondary endpoint. Results: A significant difference was observed between the calcium-vitamin D (CaD) and the calcium (Ca) only groups for changes occurring during the 90 days of the study in PTH (-14.5 +/- 40% and +2.5 +/- 46%) (p=0.009) and 25(OH)D (+67 +/- 77% and +18 +/- 55%) (p<0.001) circulating levels. PTH changes between baseline and day 90 were significant in the CaD group, but not in the Ca group. The odds ratio for a patient in group Ca to experience an absolute (<12 ng/mL) deficiency in circulating 25(OH)vitamin D levels, compared to a group CaD patient was statistically increased (OR: 3.22, 95% CI: 1.33-7.80). Conclusions: Our results support the recommendation of supplementing postmenopausal women with low circulating levels of 25(OH)vitamin D with a combination of calcium and vitamin D, rather than with calcium alone. [less ▲]

Detailed reference viewed: 40 (4 ULiège)
Full Text
Peer Reviewed
See detailPain relief is not a confounder in joint space narrowing assessment of full extension knee radiographs
Pavelka, K.; Rovati, L. C.; Gatterova, J. et al

in Osteoarthritis and Cartilage (2002), 10(SA), 16-17

Detailed reference viewed: 157 (5 ULiège)
Full Text
Peer Reviewed
See detailEvaluation of the Simple Calculated Osteoporosis Risk Estimation (Score) in a Sample of White Women from Belgium
Ben Sedrine, Wafa ULiege; Devogelaer, J. P.; Kaufman, J. M. et al

in BONE (2001), 29(4), 374-80

Identifying patients at risk of developing an osteoporosis-related fracture will continue to be a challenge. The "gold standard" for osteoporosis diagnosis is bone densitometry. However, economic issues ... [more ▼]

Identifying patients at risk of developing an osteoporosis-related fracture will continue to be a challenge. The "gold standard" for osteoporosis diagnosis is bone densitometry. However, economic issues or availability of the technology may prevent its use under a mass screening scenario. A risk assessment instrument, the "simple calculated osteoporosis risk estimation" (SCORE), has been reported to appropriately identify women likely to have low (t score < or = -2 SD) bone mineral density (BMD) and who should be referred for bone densitometry. The aim of our study is to evaluate the discriminatory performance of SCORE in a random sample of postmenopausal white women from Belgium. For this purpose, we gathered medical data on 4035 consecutive patients aged > or = 45 years, either consulting spontaneously or referred for a BMD measurement to an outpatient osteoporosis center located at the University of Liege, Belgium. BMD measurements, using dual-energy X-ray absorptiometry (DXA) technology, were taken at the hip (total and neck) and lumbar spine (L2-4). At the recommended cutoff point of 6, SCORE had a sensitivity of 91.5% to detect low BMD at any of the measured sites, a specificity of 26.5%, a positive predictive value of 52.8%, and a negative predictive value of 77.7%. According to SCORE, 18% of the patients would not be recommended for densitometry. Among these, 10.9% were misclassified as they had osteoporosis (t score < or = -2.5 SD) at one or more of the sites investigated. The negative predictive errors of SCORE, when failing to detect osteoporosis, were only 1% for the total hip, 3.2% for the femoral neck, and 8.8% for the lumbar spine. We conclude that, notwithstanding the high values of sensitivity, SCORE specificity is too low to be useful as a diagnostic tool for screening patients at high risk to later develop osteoporosis. Nevertheless, from a resource allocation perspective, this instrument can be used with relative confidence to exclude patients who do not need a BMD measurement, and would therefore provide an opportunity to realize substantial cost savings in comparison to a mass screening strategy. [less ▲]

Detailed reference viewed: 229 (8 ULiège)
Full Text
Peer Reviewed
See detailLong-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial
Reginster, Jean-Yves ULiege; Deroisy, Rita ULiege; Rovati, Lucio C et al

in Lancet (2001), 357

BACKGROUND: Treatment of osteoarthritis is usually limited to short-term symptom control. We assessed the effects of the specific drug glucosamine sulphate on the long-term progression of osteoarthritis ... [more ▼]

BACKGROUND: Treatment of osteoarthritis is usually limited to short-term symptom control. We assessed the effects of the specific drug glucosamine sulphate on the long-term progression of osteoarthritis joint structure changes and symptoms. METHODS: We did a randomised, double-blind placebo controlled trial, in which 212 patients with knee osteoarthritis were randomly assigned 1500 mg sulphate oral glucosamine or placebo once daily for 3 years. Weightbearing, anteroposterior radiographs of each knee in full extension were taken at enrolment and after 1 and 3 years. Mean joint-space width of the medial compartment of the tibiofemoral joint was assessed by digital image analysis, whereas minimum joint-space width--ie, at the narrowest point--was measured by visual inspection with a magnifying lens. Symptoms were scored by the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index. FINDINGS: The 106 patients on placebo had a progressive joint-space narrowing, with a mean joint-space loss after 3 years of -0.31 mm (95% CI -0.48 to -0.13). There was no significant joint-space loss in the 106 patients on glucosamine sulphate: -0.06 mm (-0.22 to 0.09). Similar results were reported with minimum joint-space narrowing. As assessed by WOMAC scores, symptoms worsened slightly in patients on placebo compared with the improvement observed after treatment with glucosamine sulphate. There were no differences in safety or reasons for early withdrawal between the treatment and placebo groups. INTERPRETATION: The long-term combined structure-modifying and symptom-modifying effects of gluosamine sulphate suggest that it could be a disease modifying agent in osteoarthritis. [less ▲]

Detailed reference viewed: 46 (11 ULiège)
Full Text
Peer Reviewed
See detailPrevention of early postmenopausal bone loss by strontium ranelate : a randomised, two-year, double-blind, placebo-controlled trial
Reginster, Jean-Yves ULiege; DEROISY, Rita ULiege; Tsouderos, Y et al

in Journal of Bone and Mineral Research (2001), 16(S1), 219

Detailed reference viewed: 16 (1 ULiège)
Full Text
Peer Reviewed
See detailEvaluation of the simple calculated osteoporosis risk estimation in a sample of Caucasian women from Belgium
Ben Sedrine, Wafa ULiege; Devogelaer, JP; Kaufman, JM et al

in Clinical Rheumatology (2001), 20

Detailed reference viewed: 9 (1 ULiège)
Full Text
Peer Reviewed
See detailThe timing, dose and choice of calcium and vitamin D
Reginster, Jean-Yves ULiege; Zegels, Brigitte ULiege; DEROISY, Rita ULiege et al

in BONE (2001), S28

Detailed reference viewed: 7 (1 ULiège)
Full Text
Peer Reviewed
See detailLong-term disease modifying effect by glucosamine sulfate in knee osteoarthritis : relationship between structure and symptom changes
Reginster, Jean-Yves ULiege; DEROISY, Rita ULiege; Lee, RL et al

in Annals of the Rheumatic Diseases (2000), 59(S1), 55

Detailed reference viewed: 32 (2 ULiège)
Full Text
Peer Reviewed
See detailBiochemical markers of bone and cartilage remodeling are poorly correlated with clinical and radiological severity of knee osteoarthritis
Reginster, Jean-Yves ULiege; COLLETTE, Julien ULiege; Rovati, Lucio C et al

in Arthritis and Rheumatism (2000), 43(Suppl.1), 339

Detailed reference viewed: 8 (1 ULiège)
Full Text
Peer Reviewed
See detailCartilage degradation in knee osteoarthritis patients with elevated levels of urinary collagen type II C-telopeptide fragments
Christgau, S; Henrotin, Yves ULiege; Enriksen, D et al

in Arthritis and Rheumatism (2000), 43(S1), 1243

Detailed reference viewed: 16 (2 ULiège)